Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "14-alpha demethylase inhibitors - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "14-Alpha Demethylase Inhibitors - Pipeline Insight, 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-Alpha Demethylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
14-Alpha Demethylase Inhibitors Emerging Drugs Chapters
This segment of the 14-Alpha Demethylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
14-Alpha Demethylase Inhibitors Emerging Drugs
Oteseconazole: Mycovia Pharmaceuticals Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations. The drug is in preregistration stage for the treatment of Vulvovaginal candidiasis.
Isavuconazonium: Basilea Pharmaceutica Isavuconazole is an intravenous and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. Isavuconazole is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The drug is currently in phase 3 stage of development for the treatment of Candidiasis.
14-Alpha Demethylase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different 14-Alpha Demethylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on 14-Alpha Demethylase Inhibitors
There are approx. 12+ key companies which are developing the 14-Alpha Demethylase Inhibitors. The companies which have their 14-Alpha Demethylase Inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Mycovia Pharmaceuticals.
14-Alpha Demethylase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 14-Alpha Demethylase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 14-Alpha Demethylase Inhibitors drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence 14-Alpha Demethylase Inhibitors R&D. The therapies under development are focused on novel approaches for 14-Alpha Demethylase Inhibitors.
Current Scenario and Emerging Therapies:
- How many companies are developing 14-Alpha Demethylase Inhibitors drugs?
- How many 14-Alpha Demethylase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for 14-Alpha Demethylase Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 14-Alpha Demethylase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for 14-Alpha Demethylase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Mycovia Pharmaceuticals
- Basilea Pharmaceutica
- Hill Dermaceuticals
- Zambon
- Pulmocide
- Angelini Pharmaceuticals
- Biolab Sanus Farmaceutica
- Astellas Pharma
- Basilea Pharmaceutica
- Pulmatrix
- Seren Pharmaceuticals
- Merck & Co
- Laboratoires SMB
- ProFem
Key Products
- Oteseconazole
- Isavuconazonium
- Miconazole
- ZP 059
- PC-945
- Benzydamine/econazole
- BL-123
- BAL 4815
- PUR 1900
- Fosravuconazole
- Posaconazole
- ITZ DPI
- Prof-001
Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
14-Alpha Demethylase Inhibitors Report Insights
- 14-Alpha Demethylase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
14-Alpha Demethylase Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ab33ez
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
